BioGend Therapeutics Co., Ltd. (TPEX:6733)
Taiwan · Delayed Price · Currency is TWD 25.95
+0.20 (0.78%)
May 29, 2026, 1:30 PM CST
BioGend Therapeutics Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -67.11 | -84.61 | -116.47 | -156.33 | -184.46 | -138.49 |
Depreciation & Amortization | 49.24 | 49.77 | 51.19 | 55.02 | 53.18 | 28.19 |
Loss (Gain) From Sale of Investments | - | - | - | - | - | -26.7 |
Loss (Gain) on Equity Investments | 1.83 | 1.84 | 2.46 | -10.34 | - | 11.35 |
Stock-Based Compensation | 7.33 | 6.16 | 3.64 | - | - | - |
Provision & Write-off of Bad Debts | 0.83 | 0.8 | - | - | - | - |
Other Operating Activities | -18.66 | -20.17 | -13.02 | -13.1 | -29.26 | -5.81 |
Change in Accounts Receivable | -9.25 | -12.4 | -20.67 | -15.42 | -6.22 | -4.72 |
Change in Inventory | -12.38 | -4.56 | 0.58 | -11.65 | 4.13 | 1.38 |
Change in Accounts Payable | -0 | -2.13 | 2.06 | 0.08 | 1.6 | -0.88 |
Change in Unearned Revenue | - | - | -2.5 | - | - | - |
Change in Other Net Operating Assets | 3.43 | 1.64 | -16.17 | 13.02 | 2.23 | -1.12 |
Operating Cash Flow | -44.76 | -63.66 | -98.91 | -138.72 | -168.78 | -136.8 |
Capital Expenditures | -1.87 | -1.87 | -0.65 | -26.04 | -18.18 | -0.67 |
Cash Acquisitions | - | - | - | - | - | 26.41 |
Sale (Purchase) of Intangibles | - | - | - | 0.32 | - | - |
Investment in Securities | 150 | 100 | -6.24 | -64 | 223.2 | -159.97 |
Other Investing Activities | -31.92 | -31.71 | -1.31 | 0.08 | -3.32 | -0.04 |
Investing Cash Flow | 116.21 | 66.43 | -8.2 | -89.64 | 201.7 | -134.27 |
Long-Term Debt Repaid | - | -3.7 | -3.64 | -3.58 | -4.81 | -1.78 |
Net Debt Issued (Repaid) | -3.71 | -3.7 | -3.64 | -3.58 | -4.81 | -1.78 |
Issuance of Common Stock | 360 | - | - | 400 | - | 289.63 |
Financing Cash Flow | 356.29 | -3.7 | -3.64 | 396.42 | -4.81 | 287.85 |
Foreign Exchange Rate Adjustments | -0.8 | -0.2 | -0.74 | -1.19 | -0.79 | -0.49 |
Net Cash Flow | 426.95 | -1.12 | -111.49 | 166.87 | 27.32 | 16.28 |
Free Cash Flow | -46.62 | -65.52 | -99.56 | -164.76 | -186.96 | -137.47 |
Free Cash Flow Margin | -20.29% | -29.47% | -59.38% | -149.91% | -594.54% | -1483.13% |
Free Cash Flow Per Share | -0.38 | -0.53 | -0.81 | -1.37 | -1.81 | -1.36 |
Cash Interest Paid | 0.14 | 0.15 | 0.22 | 0.26 | 0.09 | 0.02 |
Cash Income Tax Paid | 0.16 | 0.42 | 0.5 | 0.2 | -0.18 | - |
Levered Free Cash Flow | -18.94 | -32.15 | -57.11 | -95.39 | -98.09 | -83.82 |
Unlevered Free Cash Flow | -18.85 | -32.05 | -56.97 | -95.23 | -98.04 | -83.81 |
Change in Working Capital | -18.2 | -17.44 | -26.7 | -13.97 | -8.25 | -5.34 |